|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Satiety, Inc. |
|---|---|
| Information provided by: | Satiety, Inc. |
| ClinicalTrials.gov Identifier: | NCT00661245 |
Purpose
The TOGA® trial is a prospective, multi-center, randomized sham-controlled trial designed to determine the safety and effectiveness of the TOGA System for the treatment of morbid obesity. The study will also determine the effect of the treatment on co-morbidities and quality of life.
Subjects will be blinded to treatment or sham. Sham arm may crossover to TOGA treatment at 12 months.
| Condition | Intervention | Phase |
|---|---|---|
|
Obesity |
Device: TOGA Device: Control |
Phase III |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Treatment |
| Estimated Enrollment: | 275 |
| Study Start Date: | July 2008 |
| Estimated Primary Completion Date: | October 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: TOGA
The TOGA procedure is an incision-free treatment using a set of flexible staplers introduced into the mouth and esophagus to create a sleeve in the stomach (transoral formation of a gastric sleeve). The TOGA sleeve limits the amount of food that can be eaten and gives the patient a feeling of fullness after a small meal.
|
Device: TOGA
Transoral Gastroplasty (TOGA®) System for gastric stapling.
|
|
Sham Comparator: Control
A gastric sleeve is not formed.
|
Device: Control
The control device (bougie dilator) is a FDA-cleared (Class II) device.
|
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, California | |
| Cedars-Sinai Medical Center | |
| Los Angeles, California, United States, 90048 | |
| University of California, San Francisco | |
| San Francisco, California, United States, 94110 | |
| United States, Massachusetts | |
| UMass Memorial Medical Center (University of Massachusetts) | |
| Worcester, Massachusetts, United States, 01655 | |
| United States, Minnesota | |
| University of Minnesota Medical Center | |
| Minneapolis, Minnesota, United States, 55455 | |
| United States, Missouri | |
| University of Missouri Health Care | |
| Columbia, Missouri, United States, 65212 | |
| Washington University in St. Louis - School of Medicine | |
| St. Louis, Missouri, United States, 63110 | |
| United States, New York | |
| Columbia University Medical Center | |
| New York, New York, United States, 10032 | |
| United States, Ohio | |
| University Hospitals Geauga Medical Center | |
| Chardon, Ohio, United States, 44024 | |
| University Hospitals Case Medical Center | |
| Cleveland, Ohio, United States, 44106 | |
| United States, Texas | |
| University of Texas Medical School at Houston | |
| Houston, Texas, United States, 77056 | |
| Belgium | |
| Hospital Erasme, Universite Libre de Bruxelles | |
| Brussels, Belgium | |
More Information
| Responsible Party: | Allan L. Abati, Ph.D., VP of RA, QA & Clinical Programs, Satiety, Inc. |
| ClinicalTrials.gov Identifier: | NCT00661245 History of Changes |
| Other Study ID Numbers: | S107 |
| Study First Received: | April 15, 2008 |
| Last Updated: | May 4, 2009 |
| Health Authority: | United States: Food and Drug Administration |
|
Obesity Obesity, Morbid Overnutrition Nutrition Disorders |
Overweight Body Weight Signs and Symptoms |